Curis (FRA:CUS0) E10: €-17.50 (As of Mar. 2026)


FRA:CUS0 Curis Inc FRA:CUS0
59 GF Score
Price €0.40
GF Value €0.79
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Curis E10?

Curis FRA:CUS0 +51.52% 59 E10 is €-17.50 as of Mar. 2026. GuruFocus rates FRA:CUS0 with a GF Score™ of 59/100 and a GF Value™ of €0.79 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Curis's adjusted earnings per share data for the three months ended in Mar. 2026 was €-1.081. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-17.50 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 9.20% per year. During the past 5 years, the average E10 Growth Rate was 3.40% per year. During the past 10 years, the average E10 Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Curis was 37.10% per year. The lowest was -11.00% per year. And the median was -2.60% per year.

As of today (2026-07-01), Curis's current stock price is €0.40. Curis's E10 for the quarter that ended in Mar. 2026 was €-17.50. Curis's Shiller PE Ratio of today is .


Curis  (FRA:CUS0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Curis E10 Related Terms


Curis E10 Historical Data

* Premium members only.

The historical data trend for Curis's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis E10 Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.07 -27.27 -16.55 -27.62 -19.44

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.15 -18.79 -19.42 -19.44 -17.50

FRA:CUS0 vs CALC, ICU, TRAW: E10 Comparison

For the Biotechnology subindustry, Curis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Shiller PE Ratio falls into.


FRA:CUS0
59GF Score
Curis Inc FRA:CUS0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Curis's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.081/330.2130*330.2130
=-1.081

Current CPI (Mar. 2026) = 330.2130.

Curis Quarterly Data

per share eps CPI Adj_EPS
201606 -8.010 241.018 -10.974
201609 -18.711 241.428 -25.592
201612 -7.584 241.432 -10.373
201703 -10.285 243.801 -13.930
201706 -8.722 244.955 -11.758
201709 -8.893 246.819 -11.898
201712 -3.718 246.524 -4.980
201803 -5.353 249.554 -7.083
201806 -4.451 251.989 -5.833
201809 -3.771 252.439 -4.933
201812 -3.164 251.233 -4.159
201903 -5.310 254.202 -6.898
201906 -3.894 256.143 -5.020
201909 -3.450 256.759 -4.437
201912 -4.680 256.974 -6.014
202003 -5.068 258.115 -6.484
202006 -3.019 257.797 -3.867
202009 -1.868 260.280 -2.370
202012 -1.808 260.474 -2.292
202103 -1.848 264.877 -2.304
202106 -1.992 271.696 -2.421
202109 -2.040 274.310 -2.456
202112 -2.655 278.802 -3.145
202203 -3.269 287.504 -3.755
202206 -3.216 296.311 -3.584
202209 -2.858 296.808 -3.180
202212 -2.266 296.797 -2.521
202303 -2.232 301.836 -2.442
202306 -2.280 305.109 -2.468
202309 -1.996 307.789 -2.141
202312 -1.862 306.746 -2.004
202403 -1.886 312.332 -1.994
202406 -1.886 314.175 -1.982
202409 -1.532 315.301 -1.604
202412 -1.194 315.605 -1.249
202503 -1.156 319.799 -1.194
202506 -0.590 322.561 -0.604
202509 -0.417 324.800 -0.424
202512 1.050 324.054 1.070
202603 -1.081 330.213 -1.081

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-17.50 mean?
Curis (FRA:CUS0) has a E10 of €-17.50 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Curis and its competitors.
Is Curis' E10 too high?
Curis' current E10 is €-17.50. Overall, Curis has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Curis' E10 compare to CALC and ICU?
Curis' E10 of €-17.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Curis and its competitors. Curis's current E10 is €-17.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (FRA:CUS0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.79, compared to a current price of €0.40 — trading 49.4% below its estimated fair value. The current E10 is €-17.50. Curis' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Curis (FRA:CUS0), the current E10 is €-17.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Curis (FRA:CUS0) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be undervalued. The current stock price of €0.40 is trading 49.4% below its estimated GF Value™ of €0.79. GuruFocus considers Curis to be Possible Value Trap.

Key valuation signals for FRA:CUS0:

  • E10: €-17.50
  • GF Value™: €0.79 vs. price of €0.40 (49.4% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
59GF Score

Get the complete analysis for FRA:CUS0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.79
GF Value